MarketPR
Liquidia (LQDA) resolved its legal dispute with United Therapeutics on October 13, confirming that the inhaled lung drug Yutrepia will remain available to patients with pulmonary arterial hypertension without disruption.
This settlement followed a federal judge's ruling on September 30 that Yutrepia infringes a United Therapeutics patent, a decision that triggered a nearly 50% drop in the stock that day.
Since then, Liquidia shares have lost 59% over the past month, a period during which the S&P 500 gained 2.5%. The company's historical performance shows a pattern of severe drawdowns followed by recovery.
Since 2018, Liquidia has experienced seven market shocks, with the stock falling an average of 28.7% compared to a 17.1% decline for the S&P 500.
Keep reading